Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
Mohit Yadav reaffirmed government's commitment to improve competitiveness, enhance export capabilities and support the country's transition from volume-driven to value-driven exports
Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California
Dengue, a mosquito-borne viral disease, is emerging as a growing public health threat across Africa
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
Ranluspec is the only interchangeable ranibizumab biosimilar approved in the United States in both vial and pre-filled syringe (PFS) presentations
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
